Induced pluripotent stem (iPS) cells are pluripotent and are able to unlimitedly proliferate in vitro. This technical breakthrough in creating iPS cells from somatic cells has noteworthy implications for overcoming the immunological rejection and the ethical issues associated with the derivation of embryonic stem cells from embryos. In the current work, we present an efficient hepatic differentiation of mouse iPS cells in vitro. iPS cells were cultured free floating to induce the formation of embryoid bodies (EB) for 5 days. EB were transferred to a gelatin-coated plate and treated with 100 ng/ml activin A and 100 ng/ml basic fibroblast growth factor (bFGF) for 3 days to induce definitive endoderm. Cells were further cultured for 8 days with 100 ng/ml hepatocyte growth factor (HGF) to generate hepatocytes. Characterization was performed by RT-PCR assay. Functional analysis for albumin secretion and ammonia removal was also carried out. iPS cellderived hepatocyte-like cells (iPS-Heps) were obtained at the end of the differentiation program. Expression levels of a gestational hepatocyte gene and lineage-specific hepatic genes intensified in iPS-Heps. The production of albumin increased in a time-dependent manner. iPS-Heps were capable of metabolizing ammonia. We present here instant hepatic differentiation of mouse iPS cells using combined 3-day treatments of activin A and bFGF with subsequent 8-day HGF. Our study will be an important step to generate hepatocytes from human iPS cells as a new source for liver-targeted cell therapies.
INTRODUCTION
patocyte transplantation have been conducted. Partial improvements of bilirubin metabolism (1,7,8), a urea cycle disorder (10) , glycogen storage disease type 1 (15) , Hepatocytes have a wide range of functions in the body. Once hepatocytes are massively damaged, even an inborn error in fatty acid metabolism (9, 19) , and a clotting factor deficiency (6) have been reported. Fur-temporally, the patients will be placed in a very lethal status. Orthotopic liver transplantation has been applied thermore, in patients with acute liver failure, hepatocyte allotransplants decreased cerebral perfusion pressure, in the case of liver failure. Although the surgical techniques and the postoperative managements are improved, lowered ammonia levels, and even improved an overall survival (5, 21) . However, the major limitation of cell surgery-associated mortality is still considerable.
To overcome the complications associated with he-therapies for liver diseases is the donor liver shortage (11) . Besides, chronic immunosuppression is still re-patic organ transplantation, several clinical trials of he-quired for allotransplantation of hepatocytes. In general, at 37°C in 5% CO 2 . Every passage was carried out before cells reached confluency (22) . the patient-derived cells are extremely attractive in cell therapies.
In Vitro Differentiation of Hepatocyte-Like Cells Historically, in 1992, autologous hepatocyte trans-From Undifferentiated iPS Cells plantation was first reported in 10 patients with chronic liver disease (14). Hepatocytes were directly trans-Differentiation was carried out in three stages, as planted into the spleen after isolating the cells from surshown in Figure 1 . gically resected recipient's left lateral segment of the Stage 1: Formation of Embryoid Bodies (Days 0-4). cirrhotic liver. Although autotransplanted hepatocytes iPS cells growing on feeder cells were dispersed by were detected in the spleen at 1-6 months, significant treatment with trypsin-EDTA (Sigma-Aldrich Japan, clinical effects were not obtained. The unsatisfactory re-Tokyo, Japan) and collected by centrifugation at 800 sults may include the site of hepatocyte transplantation, rpm for 3 min. Cells were then resuspend in Knockout the number of the transplanted cells, and viability of the DMEM (Gibco, Invitrogen, CA) supplemented with isolated cells.
15% knockout serum replacement (KSR) (Gibco), 1% Transplantation of the cells derived from extrahepatic nonessential amino acids (MP Biomedicals, CA), 1% 2sites of patients may be another potentially effective cell mercaptoethanol (Gibco), 1% penicillin/streptomycin therapy for liver diseases. It has been reported that bone (Sigma-Aldrich Japan), and 1% l-glutamic acid (DS marrow cells can populate the damaged liver and differ-Pharma Biomedical, Osaka, Japan). iPS cells were then entiate into albumin-producing hepatocytes (18). The transferred to ultra-low attachment six-well plates (Corauthors performed an autologous bone marrow cell infuning, NY) and cultured free floating in the culture mesion in nine liver cirrhotic patients and reported ameliodium at a density of 2 × 10 5 cells/2 ml/well to induce ration of albumin production (24). In animal models, the formation of embryoid bodies (EB) (at days 0). Half mesenchymal stem cells originating from bone marrow of the medium was replaced daily. (12) or adipose tissue (2,26) are expected as an alterna-Stage 2: Induction of Definitive Endoderm (Days 5tive cell source for obtaining differentiated hepatocytes. 7). At days 5, EB were collected from the single well Recently, induced pluripotent stem (iPS) cells had and centrifuged at 1000 rpm for 3 min. EB were then been successfully established from mouse and human resuspend in 9 ml of Knockout DMEM, 1% penicillin/ fibroblasts using defined factors (13, 17, 23, 25) . iPS cells streptomycin, 1% l-glutamic acid, 100 ng/ml activin A are pluripotent and are able to unlimitedly proliferate in (R&D Systems, MN), 100 ng/ml basic fibroblast growth vitro. This technical breakthrough in creating iPS cells factor (bFGF) (Peprotech, NJ) to induce definitive endofrom somatic cells has noteworthy implications for overderm (DE). In each well of a gelatin-coated 12-well coming the immunological rejection and the ethical isplate, 1.5 ml of the medium containing EB was seeded. sues associated with the derivation of embryonic stem EB were cultured for additional 3 days. KSR was sup-(ES) cells from embryos.
plemented at days 6-7 and the concentrations were var-In the current work, we present an efficient hepatic ied: 0.2% for days 6 and 2.0% for days 7. Half of the differentiation of mouse iPS cells in vitro. At the end of medium was replaced daily. the differentiation program, iPS cell-derived hepatocyte-Stage 3: Differentiation of Hepatocyte-Like Cells like cells (iPS-Heps) were obtained.
( mouse iPS cell culture was collected at regular intervals. HGF (100 ng/ml) for 8 days in a gelatin-coated culture plate. Morphologically, the cells revealed polygonal The amount of albumin secreted into the culture medium was measured by an albumin enzyme-linked-immuno-shape with two nucleoli and enriched cytoplasmic granules, which are compatible with the characteristics of sorbent assay kit (ALBUWELL M; Exocell, Philadelphia, PA), as per the manufacturer's instructions.
normal mouse hepatocytes in culture ( Fig. 1E ).
Mouse iPS Cells Cultured With Activin A, bFGF, Measurement of Ammonia-Metabolizing Capacities and HGF Expressed the Genes of Albumin of Mouse iPS Cells
RT-PCR analysis showed that the expression of albu-At the end of hepatic differentiation, ammoniamin, a marker for matured hepatocytes, progressively inmetabolizing capacities of iPS-Heps were measured.
creased over the course of differentiation program ( gluconeogenesis phosphoenolpyruvate carboxykinase 1 Ammonium concentration was determined using an am-(PCK1), and transferrin (Trf) also intensified in a timemonium concentration assay kit (Wako Pure Chemical, dependent manner. iPS-Heps expressed asialoglycoprot-Osaka, Japan), as per the manufacturer's instructions. ein receptor (ASGR) gene, which is also called hepatic iPS cells in free-floating culture were used as controls.
lectin (data not shown). The result confirmed progressive differentiation toward hepatocytes in a population Statistical Analysis of cells. α-Fetoprotein (AFP) expression, which is pres-Student's t-test was used to estimate the difference ent in endoderm but is not expressed by mature hepatoand p < 0.05 was deemed statistically significant.
cytes, was still detected 16 days after culture, indicating that differentiation toward a mature hepatocyte was not RESULTS uniform.
Mouse iPS Cells Cultured With Activin A, bFGF, and HGF Showed Morphological Characteristics
Mouse iPS Cells Cultured With Activin A, bFGF, and of Hepatocytes HGF Produced Albumin and Metabolized Ammonia iPS-Heps secreted albumin at 396.0 ± 65.5 pg/ml/24 Mouse iPS cells were cultured with activin A (100 ng/ml) and bFGF (100 ng/ml) for 3 days and then with h/1 × 10 5 cells and metabolized 18.1 ± 5.9% of loaded ammonia (Fig. 3) . The result showed that iPS-Heps hold whose etiology includes chemical and viral hepatitis. It occurs as a result of massive hepatocyte necrosis and is a metabolic activity as functional hepatocytes.
the most severe manifestation of liver insufficiency, DISCUSSION with mortality rates greater than 80%. The ability to obtain unlimited numbers of human hepatocytes may im-The liver is one of the largest organs in the body and performs numerous functions that are vitally important prove the development of cell therapies for liver diseases. to maintain metabolic homeostasis. These functions include synthesis of serum proteins, regulation of nutri-ES cells are pluripotent, and potentially can differentiate into any cell type. We have previously shown that ents, production of bile, and the metabolism and conjugation of compounds for excretion in the bile or urine.
mouse ES cells can be differentiated by sequential culture in activin A, bFGF, HGF, and dexamethasone, and Hepatocytes, which are the predominant cell type within the liver, account for two thirds of the liver mass. The can be isolated by an albumin promoter-based cell sort to generate functional hepatocytes (20) . Such ES cell-liver is normally able to regenerate after acute injury and regain its function under appropriate physiological derived hepatocytes express liver-specific genes, but not genes representing other lineages. We have successfully stimuli. However, when the normal regenerative process is compromised and the residual functional capacity of applied the differentiation protocol to human ES cells with a minor modification (4). Such studies provide a the damaged liver is unable to sustain life, liver failure occurs. The two principal causes of the liver failure are foundation for efficient development of the cells with numerous characteristics of hepatocytes from both cirrhosis and fulminant hepatic failure. Liver cirrhosis, whose etiology includes alcoholism and chronic hepati-mouse and human cells. Generation of functional hepatocytes from precursors tis, is an irreversible process that occurs when fibrotic tissue replaces normal liver tissue as a result of chronic derived from individual patients using an iPS cell establishment technology will lead to the development of in-injury. Fulminant hepatic failure is a clinical syndrome, defined by impaired mental and neuromuscular function, dividualized patient specific drug regimens and finally may be used to overcome the need for life-long immune In conclusion, we have here presented instant hepatic differentiation of mouse iPS cells using combined treat-suppression after transplantation of the cells. Therefore, in the present study, we applied our strategy to mouse ments of activin A (100 ng/ml) and bFGF (100 ng/ml) with subsequent 8-day HGF (100 ng/ml). Our study will iPS cells and found that the resultant iPS cells showed the expression of hepatocyte-enriched genes, albumin be an important step to generate hepatocytes from human iPS cells as a new source for liver-targeted cell secretion, and potential for metabolizing ammonia. ASGR-based cell sorting is now under investigation for therapies. the enrichment of the hepatic population. Further studies REFERENCES are needed to determine whether the differentiation protocol and enrichment strategy can be scaled for use in
